Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21795770 | 0.80 | SMN1; SMN2 (0.40) | NNMTMAPT | |
| SCHEMBL21795777 | 0.78 | OGA (0.44) | HRH3 | |
| SCHEMBL21795773 | 0.75 | DUSP3 (0.44) | MAPT | |
| SCHEMBL22003701 | 0.71 | GRIN2B (0.48) | — | |
| SCHEMBL29022603 | 0.68 | NNMT (0.47) | NNMTOPRM1OPRD1OPRK1MAPT | |
| SCHEMBL28476110 | 0.64 | KDM4E (0.58) | NNMTMAPT | |
| SCHEMBL22031223 | 0.63 | HRH3 (0.71) | HRH3NNMT | |
| SCHEMBL4452722 | 0.63 | HRH3 (0.48) | HRH3NNMTOPRM1OPRD1OPRK1 | |
| SCHEMBL2828056 | 0.63 | OPRM1 (0.60) | HRH3OPRM1OPRK1 | |
| SCHEMBL18822758 | 0.63 | HRH3 (0.54) | HRH3NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179391-B2 | Compound with kinase inhibitory activity and preparation method and use thereof | Zhang, Fuyao (CN) | 2021-11-23 | — | — | US | disclosed |
| EP-3620456-B1 | COMPOUND WITH KINASE INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | ZHANG FUYAO (CN) | 2021-11-17 | — | — | EP | disclosed |
| CN-108794452-B | Compound with kinase inhibition activity, preparation method and application thereof | 上海时莱生物技术有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20200155550-A1 | COMPOUND WITH KINASE INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | SHANGHAI BEST-LINK BIOSCIENCE, LLC (CN) | 2020-05-21 | — | — | US | disclosed |
| EP-3620456-A1 | COMPOUND WITH KINASE INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | Selection Bioscience LLC (CN) | 2020-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155550-A1 | COMPOUND WITH KINASE INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | CDK9, CDK7, CDK6 | HRH3 3825/4885NNMT 1660/4885OPRM1 3916/4885 |
| US-11179391-B2 | Compound with kinase inhibitory activity and preparation method and use thereof | CDK9, CDK7, CDK6 | HRH3 3825/4885NNMT 1660/4885OPRM1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.